Ellie Murrell

“On the MASH program, interesting on the 70% liver fat reduction, And we certainly agree that mash is a very large opportunity. Curious your perspective on the antifibrotic mechanism that you might be seeing here, and how are you thinking about this in the context of the FGF21 class?”

“Jen, just to elaborate a little bit on what you're seeing in some of the ATTRCM commercial dynamics. You said that the expanded field force has increased physician engagement, but that hasn't turned into faster demand growth yet.”

“So the Pfizer release cited net price erosion from new payer contracts, while your growth to net has remained stable within the range you guided to. Given a TRUBI launched at a list price below to FAMIDIS, do you see any need to respond on price, or is clinical differentiation carrying access and share on its own?”

“I'm curious what your expectations are for timing for data from RCC and muscle-invasive bladder cancer, and can you elaborate on what good data would look like in these indications and then what the next steps would be in those indications if the data are positive?”

“I'm very happy to have 4D Molecular Therapeutics here with us today for a fireside, or I should say, beachside chat. Joining us from 4D is Christian Humer, Chief Financial Officer, and Chris Sims, Chief Commercial and Business Officer.”